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ROutcome After 7 Years of Carotid Artery Stenting and Endarterectomy
in Sweden – Single Centre and National Results
Lindström D., Jonsson M., Formgren J., Delle M., Rosfors S., Gillgren P.
Eur J Vasc Endovasc Surg 2012;43:499-503.
Objectives: The aim was internal vascular centre quality-control mea-
sures to compare single-centre results with the national perspective, as well as
Analysing the Swedish results from carotid artery stenting (CAS) and com-
paring a relatively high-volume single centre with the Swedish Vascular
Registry (Swedvasc) data. The second aim was to compare CAS and carotid
artery endarterectomy (CEA) outcomes for the same 7-year period.
Design: Retrospective review of a single high-volume centre (Söder-
sjukhuset (SöS)) (approximately 30 CAS year1 approximately 90 CEA
year1) versus Swedvasc National data.
Materials and methods: All consecutive selective patients treated with
CAS at SöS for a stenosis of the internal carotid artery (n  208) or CEA
(n  552) between 2004 and 2011 were compared with all patients in
Swedvasc registered for CAS (n  258) and CEA (n  6474). Primary
outcome was 30-day frequency of stroke or death. Secondary outcome was
stroke/death/acute myocardial infarction (AMI).
Results: The 30-day frequency of any stroke or death after CAS at SöS
compared to the national data was 2.9% and 7.4%, respectively (P  0.04).
The 30-day AMI/stroke/death frequency was 3.4% and 9.5%, respectively
(P  0.01). After CEA during the same time period, the Swedvasc national
data had a 4.4% frequency of 30-day stroke and death and 5.8% for
AMI/stroke/death.
Conclusions: CAS is not as safe as CEA from a national perspective but
our results indicate that a single centre can achieve acceptable results with
CAS.
Endovascular Repair of Abdominal Aortic Aneurysm does not Improve
Early Survival versus Open Repair in Patients Younger than 60 Years
Gupta P.K., Ramanan B., Lynch T.G., Gupta H., Fang X., Balters M.,
Johanning J.M., Longo G.M., MacTaggart J.N., Pipinos I.I. Eur J Vasc
Endovasc Surg 2012;43:518-24.
Objectives: Multiple randomised trials have demonstrated lower peri-
operative mortality after endovascular aneurysm repair (EVAR) compared to
open surgical repair for infrarenal abdominal aortic aneurysms (AAAs).
However, in these trials the mortality advantage for EVAR is being lost
within 2 years of repair and the patients evaluated are relatively older with no
study specifically comparing EVAR and open repair for patients younger
than 60 years of age.
Design: A retrospective analysis of prospectively collected data.
Materials and methods: Patients younger than 60 years of age who
underwent EVAR and open surgical repair for elective infrarenal AAA were
identified from the 2007–09 National Surgical Quality Improvement Pro-
gram (NSQIP) – a prospective database maintained at 237 centres across the
United States. Univariate and multivariate analyses were performed.
Results: Of the 651 patients, 369 (56.7%) underwent EVAR and 282
(43.3%) underwent open repair. Thirty-day mortality for EVAR and open
repair were 1.1% and 0.4%, respectively. This was not significantly different
on univariate (P  0.22) as well as multivariate (P  0.69) analysis after
controlling for other co-morbidities. On multivariate analysis, body mass
index, history of stroke and bleeding disorder prior to surgery were associ-
ated with a higher 30-day mortality after AAA repair (combined open and
EVAR).
Conclusions: These contemporary results demonstrate that the 30-day
mortality rate after open repair is similar to that after EVAR in patients
younger than 60 years with infrarenal AAA.
Measuring the Maximum Diameter of Native Abdominal Aortic Aneu-
rysms: Review and Critical Analysis
Long A., Rouet L., Lindholt J.S., Allaire E. Eur J Vasc Endovasc Surg
2012;43:527-36.
Objectives: Maximum diameter is a determinant parameter for the
clinical management of asymptomatic abdominal aortic aneurysm (AAA).
However, its measurement is not standardised. We review the different
methods used to measure AAA maximum diameter, with ultrasound (US) or
computed tomography (CT).
L
EMethods: A review of maximum diameter measurement methods with
S and CT was performed, focussing on screening, surveillance before
epair and decision for intervention. Diameter measurement methodology
as described according to four parameters: plane of acquisition, axis of
easurement, position of callipers and selected diameter. A quality score to
valuate methodology descriptions was defined (plane, axis, callipers place-
ent and selected diameter), ranging from 0 (worst) to 4 (best).
Results: Review showed a wide range of definitions and practices. The
ean value of the quality score was 2.52 in screening studies, 1.66 in
uidelines for screening, 2.81 in follow-up studies and 1.63 in studies
escribing decision for intervention.
Conclusion: To improve the efficiency of AAA management (in
creening programmes, follow-up and decision for intervention), and enable
omparison between future studies, a standardised methodology for AAA
aximum diameter measurement is necessary. Until such a consensus is
eached, publications should at least clearly report the method of measure-
ent.
reatment of Aortic Arch Aneurysms with a Modular Transfemoral
ultibranched Stent Graft: Initial Experience
ioupis C., Corriveau M.-M., MacKenzie K.S., Obrand D.I.,
teinmetz O.K., Abraham C.Z. Eur J Vasc Endovasc Surg 2012;43:537-44.
Objectives: To present initial experience with a new modular trans-
emoral multibranched stent graft for treating aortic arch aneurysms.
Methods: Six patients, considered high risk for open surgery, were
reated with custom made branched stent grafts. All patients had a staged left
arotid subclavian bypass before the endovascular procedure. Each branched
raft had a 12 mm side branch for the innominate artery and an 8 mm side
ranch for the left common carotid artery.
Results:Four patients out of six had uneventful placement of the
rostheses, with successful exclusion of their aneurysms. One patient devel-
ped a type I endoleak that was managed successfully with coiling and gluing
f the aneurysm sac. In one patient, cannulation of the innominate branch
as unsuccessful and an extra-anatomic bypass was necessary to perfuse the
ight carotid and vertebral arteries. This patient developed a stroke, while
ne more suffered a right cerebellar infarct.
Conclusion: We have demonstrated the technical feasibility of a modular
ransfemoral branched stent graft for treatment of aortic arch aneurysms. The
ethod is relatively safe based on initial experience. More cases and long-term
ollow up are necessary to evaluate the efficacy and safety of this new device.
easurement and Optimization of Patient Radiation Doses in Endo-
ascular Aneurysm Repair
alsh C., O’Callaghan A., Moore D., O’Neill S., Madhavan P.,
olgan M.P., Haider S.N., O’Reilly A., O’Reilly G. Eur J Vasc Endovasc
urg 2012;43:546-51.
The study assessed radiation exposure during EVAR. Two types of patient
ose were estimated: effective dose (ED), which allows estimation of radiation risk
o the EVAR patient population; and Peak Skin Dose (PSD), which allows us assess
he potential for an individual patient to receive a radiation skin injury. An ancillary
im was to examine dose optimization in EVAR procedures.
Based on 111 EVAR cases we estimated average ED as 12.4 mSv.
umulative patient dose in our centre was lower than other studies because
he follow up of EVAR patients is based on ultrasound rather than CT. PSD
alculated using a published conversion formula closely matched measure-
ents with calibrated gafchromic film. 99% of patients had an estimated PSD
f 2Gy. Results indicate that skin injuries are possible, but very unlikely in
VAR procedures at our centre.
EVAR is a high dose procedure and emphasis on dose optimisation is
mportant. We broke the EVAR procedure into 15 steps and, in a phantom
tudy, showed how skin dose changes as procedure steps are varied. The
esulting dose matrix has the potential to be used as an educational tool to
romote dose optimization.
redictors of Early Graft Failure After Infrainguinal Bypass Surgery: A
isk-adjusted Analysis from the NSQIP
ancaster R.T., Conrad M.F., Patel V.I., Cambria R.P., LaMuraglia G.M.
ur J Vasc Endovasc Surg 2012;43:580-6.
1543
C
F
o
L
G
r
c
4
t
t
i
A
c
s
d
a
i
P
a
c
c
JOURNAL OF VASCULAR SURGERY
May 20121544 AbstractsIntroduction and objectives: Infrainguinal bypass surgery (BPG) is
accompanied by significant 30-day mortality and morbidity, including early
graft failure. The goal of this study is to identify patient- and procedure-
specific factors which predict the rate of early graft failure in contemporary
practice.
Methods: Data was obtained from the private sector National Surgical
Quality Improvement Program, a prospective, validated database collected
between 2005 and 2008 from 211 hospitals, using primary and modifier
Current Procedural Terminology codes for BPG. The primary endpoint was
graft failure at 30 days. Procedural parameters, patient demographics and
clinical variables were analyzed by univariate and multivariate methods.
Results: There were 9217 BPG procedures (limb salvage, 49%; infr-
apopliteal distal anastomosis, 43%; prosthetic 32%) with patient variables:
age 67  12 years, male 64%, diabetes 44%, dialysis 7.4%. Mortality was
2.4%, major morbidity was 17.3%, and graft failure rate was 6.3% at 30 days.
Multivariate predictors of graft failure demonstrated correlation (p-value,
OR) with female gender (p  0.0054, 1.29), limb salvage indication
(p  0.0001, 1.60), infrapopliteal anastomosis (p  0.0001, 2.15), com-
posite graft (p  0.0436, 1.82), current smoking (p  0.0007, 1.36), im-
paired sensorium (p  0.0075, 2.13), emergency procedure (p  0.0001,
2.03), previous vascular procedure (p  0.0005, 1.39), and platelets
400K (p  0.0019, 1.49). High-risk composite constructs utilizing these
significant predictive factors can identify cohorts of patients with up to a
98-fold increase in odds of early graft failure.
Conclusions: These results describe common risk factors that correlate
with early graft thrombosis including the unique description of its associa-
tion with thrombocytosis. Additional risk factors thus identify a subset of
patients who are at highest risk for early BPG failure. This data may be used
to refine patient selection.
v
aost and Effectiveness of Laser with Phlebectomies Compared with
oam Sclerotherapy in Superficial Venous Insufficiency. Early Results
f a Randomised Controlled Trial
attimer C.R., Azzam M., Kalodiki E., Shawish E., Trueman P.,
eroulakos G. Eur J Vasc Endovasc Surg 2012;43:630-6.
Objectives: Quantify endovenous laser ablation (EVLA) with concur-
ent phlebectomies and ultrasound-guided foam sclerotherapy (UGFS) in
ost and effectiveness at 3 weeks and 3 months.
Design: Single-centre, prospective, randomised controlled trial.
Patients: One hundred patients (100 legs), C2–6, age 21–78, M:F
2:58, with primary varicose veins received either EVLA under local anaes-
hetic or UGFS.
Methods Assessments included duplex, Aberdeen varicose vein ques-
ionnaire (AVVQ), venous clinical severity score (VCSS), venous filling
ndex (VFI), visual analogue 7-day pain score and analgesia requirements.
dditional treatments with UGFS were performed, if required. Micro-
osting, using individually timed treatments, was based on consumables,
taff pay and overheads.
Results: Changes in AVVQ, VCSS and VFI values (3 months) did not
emonstrate any significant difference between groups. At 3 months, the
bove-knee GSV occlusion rate (without co-existing reflux) was not signif-
cantly different between the groups (74% vs 69%; EVLA vs UGFS;
 .596). Of the 9 haemodynamic failures in each group, 7 EVLA patients
nd 4 UGFS patients had co-existing cross-sectional above-knee GSV oc-
lusion at some point. However, UGFS significantly outperformed EVLA in
ost, treatment duration, pain, analgesia requirements and recovery.
Conclusions: UGFS is 3.15 times less expensive than EVLA (£230.24
s £724.72) with comparable effectiveness but 56% (versus 6%) required
dditional foam (ISRCTN:03080206).
